Lupin gets US FDA approval for Celecoxib Capsules

03 Nov 2014 Evaluate

Pharma Major Lupin has received final approval for its Celecoxib Capsules, 50 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of G.D. Searle LLC’s (a subsidiary of Pfizer Inc.) Celebrex Capsules 50 mg. The company also received tentative approvals for its Celecoxib capsules 100 mg, 200 mg and 400 mg strengths from the FDA.

Lupin’s Celecoxib Capsules 50 mg, 100 mg, 200 mg and 400 mg are the AB-rated generic equivalents of G.D. Searle LLC’s Celebrex Capsules 50 mg, 100 mg, 200 mg and 400mg and are indicated for Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis in patients 2 years and older; Ankylosing Spondylitis, and Acute Pain. Celebrex Capsules had annual U.S. sales of $2.44 billion according to IMS MAT June, 2014.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

 

Lupin Share Price

2133.05 11.40 (0.54%)
29-Jan-2026 14:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1210.20
Cipla 1324.55
Zydus Lifesciences 889.90
Lupin 2133.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×